Active Biotech AB (FRA:BTP) Growth Rank: 0 (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BTP Active Biotech AB FRA:BTP
30 GF Score
Price €0.41
GF Value €0.13
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Active Biotech AB Growth Rank?

Active Biotech AB has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Active Biotech AB Growth Rank Related Terms

FRA:BTP
30GF Score
Active Biotech AB FRA:BTP
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Active Biotech AB (FRA:BTP) Overvalued in 2026?

Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued. The current stock price of €0.41 is trading 214.2% above its estimated GF Value™ of €0.13. GuruFocus considers Active Biotech AB to be Significantly Overvalued.

Key valuation signals for FRA:BTP:

  • Growth Rank: 0
  • GF Value™: €0.13 vs. price of €0.41 (214.2% above fair value)
  • GF Score™: 30/100 with 1 warning sign

No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Active Biotech AB Business Description

Other Exchanges ACTI:Sweden0GQU:UK
Address Scheelevagen 22, P.O. Box 724, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
30GF Score

Get the complete analysis for FRA:BTP

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.41
Price
€0.13
GF Value